Patents by Inventor Niklas Ahlborg

Niklas Ahlborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10662240
    Abstract: A synergistic composition, kit and method for inhibition and/or neutralization of IL-21 mediated activation of human cells including (i) a first agent being an antibody or antibody fragment thereof directed to a first epitope of IL-21, and (ii) a second agent being an antibody or antibody fragment thereof directed to a second epitope of IL-21 is disclosed. The inhibition and/or neutralization of IL-21 mediated activation of human cells is for use in the prophylaxis and/or treatment of disease of immune-related conditions including inflammatory disease, autoimmunity and lymphomas.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: May 26, 2020
    Assignee: MABTECH AB
    Inventors: Niklas Ahlborg, Staffan Paulie
  • Publication number: 20180171010
    Abstract: A synergistic composition, kit and method for inhibition and/or neutralization of IL-21 mediated activation of human cells including (i) a first agent being an antibody or antibody fragment thereof directed to a first epitope of IL-21, and (ii) a second agent being an antibody or antibody fragment thereof directed to a second epitope of IL-21 is disclosed. The inhibition and/or neutralization of IL-21 mediated activation of human cells is for use in the prophylaxis and/or treatment of disease of immune-related conditions including inflammatory disease, autoimmunity and lymphomas.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 21, 2018
    Applicant: MABTECH AB
    Inventors: Niklas AHLBORG, Staffan PAULIE
  • Publication number: 20050170446
    Abstract: A sandwich assay method for detecting the presence of a target molecule in a sample comprising a complex biological fluid is provided. The assay comprises providing a first affinity ligand with affinity for the target molecule, which affinity ligand is capable of being immobilized to a solid support; applying the sample in such a way that binding of a target molecule, if present in the sample, to the first affinity ligand is enabled; applying a second affinity ligand with affinity for the target molecule, the application enabling binding of the second affinity ligand to the target molecule; removing second affinity ligand not bound to target molecule; and detecting the presence of the second affinity ligand, such presence being an indicator of the presence of a target molecule in the sample. The first affinity ligand is immobilized to the solid support at any stage before said detection, and at least one of the first and second affinity ligands is an affinity ligand other than an antibody.
    Type: Application
    Filed: April 29, 2003
    Publication date: August 4, 2005
    Inventors: Niklas Ahlborg, Per-Ake Nygren
  • Patent number: 5609872
    Abstract: A peptide comprising the amino acid sequence: U-O-X-glu-Z or O-X-glu-Z-ala-glu, wherein: U is an amino acid residue selected from val and ile; O is an amino acid residue selected from ala and thr: X is an amino acid residue selected from asp and glu: and Z is an amino acid residue selected from ile and val: the use of the peptide in the preparation of a vaccine; a composition for vaccination against malaria induced by Plasmodium falciparum, comprising such peptide in admixture with a pharmaceutically acceptable carrier; and a method of inducing immunity against malaria induced by Plasmodium falciparum, which comprises administering to a person in need of such immunity an effective amount of said composition.
    Type: Grant
    Filed: April 8, 1993
    Date of Patent: March 11, 1997
    Assignee: Malvac Foundation
    Inventors: Niklas Ahlborg, Klavs Berzins, Peter Perlmann